289 related articles for article (PubMed ID: 35606429)
1. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.
Dane EL; Belessiotis-Richards A; Backlund C; Wang J; Hidaka K; Milling LE; Bhagchandani S; Melo MB; Wu S; Li N; Donahue N; Ni K; Ma L; Okaniwa M; Stevens MM; Alexander-Katz A; Irvine DJ
Nat Mater; 2022 Jun; 21(6):710-720. PubMed ID: 35606429
[TBL] [Abstract][Full Text] [Related]
2. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
[TBL] [Abstract][Full Text] [Related]
4. Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy.
Doshi AS; Cantin S; Prickett LB; Mele DA; Amiji M
J Control Release; 2022 May; 345():721-733. PubMed ID: 35378213
[TBL] [Abstract][Full Text] [Related]
5. Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy.
Zheng H; Guo B; Qiu X; Xia Y; Qu Y; Cheng L; Meng F; Zhong Z
Bioact Mater; 2022 Oct; 16():1-11. PubMed ID: 35386324
[TBL] [Abstract][Full Text] [Related]
6. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
8. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
[TBL] [Abstract][Full Text] [Related]
9. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
[TBL] [Abstract][Full Text] [Related]
10. Combination of a STING Agonist and Photothermal Therapy Using Chitosan Hydrogels for Cancer Immunotherapy.
Chen C; Hu M; Cao Y; Zhu B; Chen J; Li Y; Shao J; Zhou S; Shan P; Zheng C; Li Z; Li Z
Biomacromolecules; 2023 Jun; 24(6):2790-2803. PubMed ID: 37125731
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
Xie X; Liu J; Wang X
Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
[TBL] [Abstract][Full Text] [Related]
12. Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists.
Nguyen DC; Shae D; Pagendarm HM; Becker KW; Wehbe M; Kilchrist KV; Pastora LE; Palmer CR; Seber P; Christov PP; Duvall CL; Wilson JT
Adv Healthc Mater; 2021 Jan; 10(2):e2001056. PubMed ID: 33225632
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
14. Lipo/TK-CDN/TPP/Y6 nanoparticles inhibit cutaneous melanoma formation.
Xiao A; Yin L; Chen T; Qian H
J Drug Target; 2024 Jun; ():1-10. PubMed ID: 38838039
[TBL] [Abstract][Full Text] [Related]
15. A novel self-assembled nucleobase-nanofiber platform of CDN to activate the STING pathway for synergistic cancer immunotherapy.
Dong W; Xu L; Chang C; Jiang T; Chen CP; Zhang G
Colloids Surf B Biointerfaces; 2023 Dec; 232():113597. PubMed ID: 37862947
[TBL] [Abstract][Full Text] [Related]
16. Sulfonated Perylene as Three-in-One STING Agonist for Cancer Chemo-Immunotherapy.
Zhao X; Zheng R; Zhang B; Zhao Y; Xue W; Fang Y; Huang Y; Yin M
Angew Chem Int Ed Engl; 2024 Mar; 63(11):e202318799. PubMed ID: 38230819
[TBL] [Abstract][Full Text] [Related]
17. Universal STING mimic boosts antitumour immunity via preferential activation of tumour control signalling pathways.
Wang Y; Li S; Hu M; Yang Y; McCabe E; Zhang L; Withrow AM; Ting JP; Liu R
Nat Nanotechnol; 2024 Jun; 19(6):856-866. PubMed ID: 38480836
[TBL] [Abstract][Full Text] [Related]
18. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.
Sun X; Zhang Y; Li J; Park KS; Han K; Zhou X; Xu Y; Nam J; Xu J; Shi X; Wei L; Lei YL; Moon JJ
Nat Nanotechnol; 2021 Nov; 16(11):1260-1270. PubMed ID: 34594005
[TBL] [Abstract][Full Text] [Related]
19. STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications.
Xu C; Dobson HE; Yu M; Gong W; Sun X; Park KS; Kennedy A; Zhou X; Xu J; Xu Y; Tai AW; Lei YL; Moon JJ
J Control Release; 2023 May; 357():84-93. PubMed ID: 36948420
[TBL] [Abstract][Full Text] [Related]
20. Vinylphosphonate-based cyclic dinucleotides enhance STING-mediated cancer immunotherapy.
Dejmek M; Brazdova A; Otava T; Polidarova MP; Klíma M; Smola M; Vavrina Z; Buděšínský M; Dračínský M; Liboska R; Boura E; Birkuš G; Nencka R
Eur J Med Chem; 2023 Nov; 259():115685. PubMed ID: 37567057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
